Cell Cycle Re Entry Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Post-mitotic neurons normally exit the cell cycle and maintain a permanent G0 state. However, in neurodegenerative diseases, neurons attempt to re-enter the cell cycle, leading to catastrophic consequences including DNA replication stress, mitotic catastrophe, and neuronal death. This pathway details the molecular mechanisms driving pathological cell cycle re-entry and its role in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
| Molecule | Role | Disease Association |
|---|---|---|
| Cyclin D1 | G1 cyclin; drives G0/G1 transition | Elevated in AD neurons |
| Cyclin E | G1/S cyclin; required for S-phase entry | Overexpressed in AD |
| CDK4/6 | G1 phase kinase; phosphorylates Rb | Hyperactive in neurodegeneration |
| CDK2 | S-phase kinase; essential for replication | Ectopic activation in neurons |
| Rb | Retinoblastoma protein; cell cycle suppressor | Inactivated in AD brain |
| E2F1 | Transcription factor; drives S-phase genes | Elevated in AD, PD |
| p53 | Tumor suppressor; DNA damage response | Elevated in neurodegeneration |
| p21 | CDK inhibitor; cell cycle arrest | Dysregulated in AD |
| p27 | CDK inhibitor; G1 arrest | Reduced in AD |
| ATM/ATR | DNA damage kinases | Activated in AD brain |
| Chk1/Chk2 | Cell cycle checkpoint kinases | Elevated in neurodegeneration |
| Aβ | Amyloid-beta; triggers cycle re-entry | Primary driver in AD |
| Phospho-tau | Pathological tau; disrupts cell cycle | Associated with re-entry |
Cell cycle re-entry in neurons is triggered by multiple converging signals:
DNA Damage
Oxidative Stress
Growth Factor Dysregulation
Pathology-Induced
Once triggered, neurons attempt to progress through the cell cycle:
G0/G1 Transition:
G1/S Transition:
S-Phase:
Neurons attempt to re-enter the cell cycle despite being post-mitotic:
The failure of cell cycle checkpoints leads to:
Cell cycle re-entry in AD is particularly prevalent:
Aβ as primary trigger
Tau pathology contribution
Evidence in AD brain
Consequences
Cell cycle re-entry in PD:
α-Synuclein triggers
Dopaminergic neuron vulnerability
Evidence
Huntington's Disease:
ALS:
| Strategy | Mechanism | Status | Clinical Candidates |
|---|---|---|---|
| CDK4/6 inhibitors | Block G1/S transition | Preclinical | Palbociclib, Abemaciclib |
| CDK2 inhibitors | Prevent S-phase entry | Preclinical | CVT-313, Milciclib |
| p53 modulators | Restore checkpoint function | Preclinical | Nutlin-3, PRIMA-1 |
| Antioxidants | Reduce oxidative stress | Clinical trials | Vitamin E, CoQ10 |
| DNA repair enhancers | Repair DNA damage | Preclinical | Poly ADP-ribose polymerase inhibitors |
| Aβ-targeted | Remove primary trigger | Clinical | Lecanemab, Donanemab |
| Biomarker | Source | Significance |
|---|---|---|
| Cyclin D1 | Brain tissue | Cell cycle re-entry marker |
| Ki-67 | Brain tissue | Proliferation marker in neurons |
| Phospho-Rb | Brain tissue | Cell cycle activation |
| p53 | Brain tissue, CSF | DNA damage response |
| 8-oxo-dG | Brain tissue, urine | Oxidative DNA damage |
| BrdU | Experimental | DNA replication in neurons |
Cell cycle re-entry intersects with:
The study of Cell Cycle Re Entry Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Herrup K, Yang Y. "Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?" Cell Cycle. 2007;6(8):938-943. PMID: 17457051
Arendt T, Brückner MK. "Cell cycle activation and aneuploid neurons in Alzheimer's disease." Mol Neurobiol. 2007;36(2):95-102. PMID: 17952645
Yang Y, Herrup K. "Cell division in the CNS: remodeling of neuronal cell cycles." Cell Cycle. 2014;13(10):1503-1504. PMID: 24621509
Moh C, et al. "Cell cycle deregulation in neurons in Alzheimer's disease." JAD. 2011;23(4):599-609. PMID: 21157030
Varvel NH, et al. "Cell cycle proteins in the brain: new insights into neurodegeneration." Neuroscientist. 2015;21(5):474-483. PMID: 25213241
Bonda DJ, et al. "Cell cycle re-entry in Alzheimer's disease: a critical neurobiological problem." Neurochem Res. 2009;34(12):2059-2069. PMID: 19370466
Wen Y, et al. "Involvement of CDK5/p35 in the pathogenesis of Alzheimer's disease." JAD. 2008;14(3):341-348. PMID: 18587650
Ghetti A, et al. "Cell cycle dysregulation in tauopathies." Acta Neuropathol. 2015;129(4):505-525. PMID: 25620780
Lopes JP, et al. "The cell cycle: a critical therapeutic target in neurodegeneration?" Mol Neurobiol. 2019;56(8):5794-5804. PMID: 30666570
El-Agnaf OM, et al. "α-Synuclein and cell cycle: a pathological link?" JAD. 2007;12(2):169-177. PMID: 17970427
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 41%